Advancing MASLD Care: Insights from the Gut–Liver–Endocrine Axis CME

Digestive & Liver Care (DLC) successfully conducted a Continuing Medical Education (CME) program on “Gut–Liver–Endocrine Axis: Trusting the Evidence.”
The CME was well attended and highly interactive, bringing together multidisciplinary clinicians for an evidence-based discussion on the rapidly evolving management of metabolic dysfunction-associated steatotic liver disease (MASLD).
A major focus of the meeting was the emerging role of semaglutide and other incretin-based therapies in the management of MASLD, with discussions centered on the latest scientific evidence, patient selection, clinical benefits, and practical application in everyday practice.

sincerely thank distinguished faculty and all the delegates&Novo Nordisk for their enthusiastic participation, thoughtful discussions, and commitment to advancing evidence-based care.